tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of John Newman, 121 are a BUY (84.62%), 22 are a HOLD (15.38%).
Analyst John Newman, currently employed at CANACCORD, carries an average stock price target met ratio of 34.75% that have a potential upside of 19.29% achieved within 110 days.
John Newman’s has documented 265 price targets and ratings displayed on 23 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ATRA, Atara Biotherapeutics at 13-Nov-2024.
Analyst best performing recommendations are on ATRA (ATARA BIOTHERAPEUTICS).
The best stock recommendation documented was for ACLX (ARCELLX) at 4/19/2023. The price target of $40 was fulfilled within 5 days with a profit of $4.74 (13.44%) receiving and performance score of 26.89.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$75
$36.03 (92.46%)
$53
9 days ago
(09-Dec-2024)
6/7 (85.71%)
$24.17 (47.55%)
477
Buy
$56
$17.03 (43.70%)
$37
2 months 21 days ago
(27-Sep-2024)
9/12 (75%)
$10.39 (22.78%)
227
Hold
$46
$7.03 (18.04%)
$30
6 months 5 days ago
(13-Jun-2024)
4/4 (100%)
$-0.77 (-1.65%)
169
Hold
$53
$14.03 (36.00%)
$33
6 months 14 days ago
(04-Jun-2024)
8/8 (100%)
$5.65 (11.93%)
164
Buy
$42
$3.03 (7.78%)
$67
1 years 5 months 21 days ago
(27-Jun-2023)
6/12 (50%)
$13.87 (49.31%)
234
Which stock is John Newman is most bullish on?
Which stock is John Newman is most reserved on?
What Year was the first public recommendation made by John Newman?
